MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jiac.2025.102704

Медицинская библиотека · Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2025

Isavuconazole in chronic pulmonary aspergillosis: What is the evidence?

de Oliveira Vitor Falcão, Taborda Mariane, Katayose Jéssica Toshie, Dos Santos Prates Bruno Victor, de Souza Ritter Isadora Cristina, Gonçalves Kono Magri Adriana Satie, Abdala Edson, Magri Marcello Mihailenko Chaves

СтатьяСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Newer drugs like isavuconazole have been more widely used for invasive aspergillosis, where they are included as first-line treatments in major guidelines, whereas their use in chronic pulmonary aspergillosis (CPA) remains limited. Therefore, the aim of this study is to conduct a systematic review of the literature on the use of isavuconazole in CPA.

METHODS

We searched PubMed/MEDLINE and Embase on August 9th, 2024. Our inclusion criteria included patients with CPA who were treated with isavuconazole. We summarized binary variables with counts and percentages, and continuous variables with mean and SD.

RESULTS

We found 15 articles on CPA using isavuconazole. These studies were published after 2017, with a high predominance in high-income countries, especially US (40 %, n = 6) and UK (33.3 %, n = 5). There were 10 case reports, the majority of which used isavuconazole as salvage therapy. Two articles compared isavuconazole with voriconazole. The overall response rates at the end of treatment for CPA patients were similar, and the incidence of adverse drug reactions was numerically lower in the isavuconazole group compared to voriconazole. We found five articles on blood levels of isavuconazole. The mean isavuconazole serum level was >1 mg/L in all studies, even at a 100-mg daily dose. In the retrospective studies, the rate of isavuconazole discontinuation ranged from 17 % to 36 %.

CONCLUSION

There is limited experience with isavuconazole in treating CPA. This study consolidates existing evidence on its use in CPA, highlighting its potential as a therapeutic option beyond invasive aspergillosis, though further research is needed.

Для цитирования: de Oliveira Vitor Falcão, Taborda Mariane, Katayose Jéssica Toshie, Dos Santos Prates Bruno Victor, de Souza Ritter Isadora Cristina, Gonçalves Kono Magri Adriana Satie, Abdala Edson, Magri Marcello Mihailenko Chaves. Isavuconazole in chronic pulmonary aspergillosis: What is the evidence?. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2025. DOI: 10.1016/j.jiac.2025.102704.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.